American Association for Cancer Research
crc-22-0427-s10.pptx (116.31 kB)

Supplementary Figure 8 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

Download (116.31 kB)
posted on 2023-07-19, 14:20 authored by Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra, Robert D. Arnold

Supplementary Fig. 8 shows Flow Cytometry; Prostate cancer cell lines stained with stemness markers (CD44, CD133 and CD44/133) to determine the percent of CD44+, CD133+ and double positive cells among PCa subtypes.  Treatments with CONV-TOPO, METRO-TOPO and CONV-DTX+METRO-TOPO reduced stemness. METRO-TOPO reduced CD44+ cells to a greater extent compared to CONV-TOPO and CONV-DTX treatments, whereas combination treatment with CONV-DTX+METRO-TOPO reduced stemness (CD44+ cells) the most in ARHigh/mCRPC/NEPC. A) PC-3M, B) DU145 cell lines.





The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.